Skip to content

Single-pulse TMS for the assessment of corticospinal excitability and cortical motor maps

Single-pulse TMS for the assessment of corticospinal excitability and cortical motor maps - Single-pulse TMS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46542
Enrollment
25
Registered
2018-08-09
Start date
2018-07-01
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dit onderzoek heeft geen betrekking op een aandoening. not applicable

Interventions

Participants will perform unilateral wrist flexion during which, through virtual reality, different visual feedback conditions will be tested.

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy participants 18-65 years old Informed consent

Exclusion criteria

Exclusion criteria: (Family) history of epilepsy Neurological disorder Psychological disorder Use of (epileptogenic) medication Possessing a contraindication for single-pulse TMS (as determined by a TMS screening questionnaire: 'F1. Screening Questionnaire TMS safety') Either being directly involved in the study, an employee at the research department or a family member of staff of the research department.

Design outcomes

Primary

MeasureTime frame
The primary outcome measures of the study described by the amendment are the amplitude of the motor evoked potentials, representative of corticospinal excitability, and the degree of suppression of the EMG signal during an 'ipsilateral silent period', representative for interhemispheric inhibition. Within a repeated measures design, differences in these measures will be tested across visual feedback conditions.

Secondary

MeasureTime frame
Relative phase of the left flexing hand with respect to the right virtual hand will be used as a measure of task performance. Depending on the specific research questions, described in subsequent amendments, other secondary measures might be included. For the current protocol these are not applicable.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026